TAGRISSO (Osimertinib) Information –

FDA approved: Yes (First approved November 13th, 2015)
Brand name: Tagrisso
Generic name: Osimertinib
Company: AstraZeneca Pharmaceuticals LP
Treatment for: Non-Small Cell Lung Cancer

What is Tagrisso and what is it used for?

Tagrisso (osimertinib) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) which is used for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell #lungcancer whose disease has worsened on or after EGFR-TKI therapy.

Approximate Price for 30 tablets of Tagrisso 80mg is $13,468.80, depending on the pharmacy you visit.

 

How does Tagrisso work?

The EGFR gene is a protein involved in the growth and spread of cancer cells. EGFR tyrosine kinase inhibitors (EGFR-TKIs) are targeted treatments for non-small cell lung cancer, but tend to develop resistance over time, often as the result of EGFR mutations. Tagrisso is an EGFR-TKI that works against cells with the T790M mutation, one of the primary causes of EGFR resistance.

Tagrisso Dosing Information :-

Take Tagrisso exactly as prescribed by your doctor.

Duration of therapy: Until disease progression or unacceptable toxicity

What are the common Side-Effects?

The most common side effects of Tagrisso include diarrhea, and skin and nail conditions such as dry skin, rash and infection or redness around the fingernails. Tagrisso may cause serious side effects including interstitial lung disease (ILD)/pneumonitis, QTc interval prolongation and cardiomyopathy.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

Warnings And Precautions :-

You should not use Tagrisso if you are allergic to osimertinib.

To make sure Tagrisso is safe for you, tell your doctor if you have:

  • a breathing disorder;
  • an electrolyte imbalance (such as high or low levels of calcium, potassium, or magnesium in your blood);
  • a heart rhythm disorder; or
  • a personal or family history of long QT syndrome.
  • Tagrisso can harm an unborn baby or cause birth defects. Do not use if you are pregnant, and tell your doctor right away if you become pregnant.
  • It is not known whether osimertinib passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine and for at least 2 weeks after your last dose.
  • If a man fathers a baby while using Tagrisso, the baby may have birth defects.
  • This medicine may affect fertility (your ability to have children), whether you are a man or a woman. However, you should use birth control as recommended during and after treatment with Tagrisso.

What other drugs will affect Tagrisso?

Many drugs can interact with osimertinib. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any you start or stop using, especially:

    • an antidepressant;
    • cancer medicine;
    • an antibiotic or antifungal medicine;
    • antiviral medicine to treat hepatitis or HIV/AIDS;
    • heart or blood pressure medicine;
    • medicine to treat a psychiatric disorder;
    • seizure medicine; or
    • tuberculosis medicine.

This list is not complete and many other drugs can interact with Tagrisso. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.